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Abstract
Obesity is associated with infertility in women through multiple and complex mechanisms. Brieﬂy, the adipose tissue
through the production of many factors, such as leptin, free fatty acids (FFA), and cytokines may affect both ovarian and
endometrium functions, with a ﬁnal alteration in oocyte maturation and endometrial epithelium receptivity. In addition,
through the development of peripheral insulin resistance obesity produces a condition of functional hyperandrogenism and
hyperestrogenism that contribute to produce anovulation and to reduce endometrial receptivity and, therefore participate to
cause infertility. Weight loss is able to restore fertility in most cases, but there are no practical indications to guide the
clinician to choice the best method among increased physical activity, diet, drugs, and bariatric surgery.
Introduction
Obesity is associated with a magnitude of complications.
These include metabolic complications, cardiovascular
events, tumors, gastrointestinal disorders, arthritis, and
infertility [1]. The association between obesity and inferti-
lity in women is the topic of this review. In particular, the
ovarian and extra-ovarian mechanisms at the basis of
infertility in obese women are the subject of this review. In
addition, the link between obesity and polycystic ovary
syndrome (PCOS), the most frequent cause of anovulatory
infertility, will be described, as well as the negative impact
of obesity on assisted conception and pregnancy outcomes.
Finally, the beneﬁcial effect of weight loss in obese infertile
women will be summarized.
Obesity and the hypothalamic-pituitary-
ovarian axis
Body fat in women impacts the function of the
hypothalamus-pituitary-ovarian (HPO) axis through central
and peripheral mechanisms [2, 3]. Accordingly, clinical
studies demonstrate that excessive leanness is associated
with puberty delay, whereas obesity is accompanied by
premature puberty [4]. These observations have led several
researchers to investigate the metabolic mediators and
pathways that directly or indirectly interact with the HPO
axis in puberty and fertility. The role of adipocytokines,
particulary leptin, has been widely studied. Several pieces
of evidence from cellular and animal models have shown
leptin to be an essential gate-keeper of puberty and future
fertility through its stimulatory action on gonadotropin-
releasing hormone (GnRH) pulses [5, 6]. Peripheral levels
of leptin are directly related to the amount of body fat.
Therefore, conditions of defect of body weight cause a
decrease in leptin levels that per se suppresses fertility,
whereas conditions of excess of body weight are associated
with increased leptin secretion. However, most forms of
obesity are characterized by a condition of leptin resistance,
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at least at the central level [7], probably via a down-
regulation of leptin receptor expression [8]. Accordingly,
Tortoriello et al. observed that mice with higher expression
of leptin receptors in the hypothalamus were resistant in
developing obesity and infertility [9]. Contrary to the brain,
other tissues, such as the ovaries, remain sensitive to leptin,
therefore being exposed to the high circulating leptin levels
that accompany obesity. Leptin in the human ovary inhibits
both granulosa and thecal cell steroidogenesis [10] and
interferes with the process of ovulation [11], therefore
directly impacting fertility. Finally, a central insulin resis-
tance state that accompanies obesity could be involved in
the processes of infertility observed in obesity through the
impact on the frequency and amplitude of luteinizing hor-
mone (LH) secretion pulses [12–14].
Obesity and sex steroids
Several alterations of sex steroids follow the increase in
body weight. In particular, obesity is associated with an
increase in both estrogens (17β-estradiol-E2 and estrone-
E1) and androgens (testosterone-T, dihydrotestosterone-
DHT, androstenedione, and dehydroepiandrosterone),
because adipose tissue directly synthesizes androgens and
converts androgens to estrogens [15]. In addition, obesity is
associated with a decrease in sex hormone binding globulin
(SHBG) circulating levels [16], with a consequent increased
availability of androgens and estrogens to target tissues.
These relationships are evident already across puberty [17]
and are particularly pronunced in central obesity [18, 19]. In
addition, adipose tissue is able to store androgens and
estrogens leading to an inﬂated steroid pool in women with
obesity [18, 20].
Overall, these phenomena lead to a condition of “relative
functional hyperandrogenism” that may affect ovarian
function therefore contributing to the development of
infertility in obesity.
Obesity and insulin
Obesity, especially central obesity, is characterized by a
condition of insulin resistance and “compensatory hyper-
insulinemia” due to many factors such as free fatty acids
(FFA), leptin, cytokines, and androgens [21]. This insulin
resistance state interests many tissues, but not all. In parti-
cular, muscle, liver, and adipose tissue become resistant to
insulin, whereas the ovaries remain sensible to insulin and,
therefore, are exposed to the burden effect of hyper-
insulinemia. In the ovaries, insulin stimulates theca cells to
produce androgens both through a direct effect and by
increasing the local sensitivity to LH [22]. The excess of
intra-ovarian androgen production may produce premature
follicular atresia thus favoring anovulation [22]. In addition,
hyperinsulinemia leads to reduced hepatic synthesis of
SHBG with a consequent increased availability of free
androgens [23], thus aggravating peripheral hyperan-
drogenism that triggers an overproduction of acyclic E1
which, in turn, determines an excessive production of LH
[24]. Increased secretion of LH may arrest follicular growth
at earlier stages, may promote early luteinization of gran-
ulose cells and may produce a damage of oocyte quality
[25–30]. Through all these mechanisms, insulin resistance
and compensatory hyperinsulinemia may contribute to
menstrual, ovulatory, and fertility disturbances that
accompany obesity, particularly central obesity, in women.
Obesity and the somatotropic axis
Obese patients are characterized by a decrease of plasma
GH levels due to a reduction of GH secretion and an
increased GH clearance rate [31–33]. Many factors parti-
cipate in reducing plasma GH levels, in particular dysre-
gulation of GH-releasing hormone (GHRH), somatostatin
(SS), and ghrelin pathways, as well as hyperinsulinemia and
excess of circulating FFA [34]. Data on circulating IGF-1
levels in obesity are contradictory. In fact, several clinical
studies showed that in people with obesity total IGF-1 are
unaltered, but other studies demonstrated increased levels of
IGF-1 [35] and of free IGF-1 for the insulin dependent
reduction in IGF Binding Protein (IGFBP)-1 and IGFBP-2
levels [36], which could be responsible for an enhanced
feedback inhibition of GH release [35]. These ﬁndings
provide evidence that obesity is characterized by a condition
of hyposomatotropinism [37] that could contribute to affect
ovarian and endometrial functions, therefore participating to
the fertility alterations that accompany obesity. In fact, GH
stimulates growth of small follicles and prevents their
atresia, collaborates with gonadotrophins in stimulating
later stages of folliculogenesis and luteinization, and facil-
itates selection and development of dominant follicle. In
addition, GH increases the ovarian production of oestrogens
and progesterone and stimulates endometrium and myo-
metrium in the uterus, all mechanisms that are a prerequisite
for successful reproduction [38].
Obesity and the ovary
Sex steroids, insulin, and the somatotropic axis act at the
level of the ovary [38]. Therefore, the dysfunctions that
affect these systems when body weight increases may be
involved in producing functional alterations in the ovary.
However, there is emerging evidence that obesity may
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directly impact the oocyte, impairing its quality. Animal
studies have, in fact, demonstrated that oocytes from obese
mice are smaller, show delayed meiotic maturation and
increased follicular apoptosis and have signiﬁcant spindle or
chromosome misalignment defects [39, 40]. These defects
are likely to generate embryos with massive aneuploidy,
therefore cause of spontaneous miscarriages. Similar results
were obtained in human studies where the comparison of
failed fertilized oocytes from patients with severe obesity or
who were normal-weight demonstrated that women with
obesity have a signiﬁcantly higher prevalence of “dis-
arrayed meiotic spindles with non-aligned chromosomes”
[41]. One proposed mechanism at the basis of the altered
oocyte quality in women with obesity includes altered
mitochondrial activity. In fact, mitochondria perform
numerous regulatory functions during oocyte maturation,
fertilization, preimplantation, and normal embryo develop-
ment [42–44]. Furthermore, mitochondria from obese
female mice present an aberrant distribution within the
oocyte [45] and are more oxidized with a rate of Reactive
Oxygen Species (ROS) production 2.1-fold higher with
respect to lean controls and with depleted levels of glu-
tathione [45]. Accordingly, the mitochondrial DNA copy
number is signiﬁcantly higher in oocytes from obese mice
with respect to lean controls [45], probably as compensatory
mechanism in response to oxidative-stress-induced mito-
chondrial damage [40].
Also the lipotoxicity may directly alter the oocyte qual-
ity, thus contributing to infertility in obese women [46–48].
In particular, both animal and human studies demonstrate
that the accumulation of FFA within the ovary is associated
with endoplasmic reticulum (ER) stress, mitochondrial
dysfunction of the oocytes, and ﬁnally apoptosis of the
cumulus–oocyte complexes [49, 50]. These data provide
new informations about the mechanisms that may lead to
impaired ovulation, reduced oocyte and embryo quality, and
therefore to infertility in women with obesity.
Obesity and the endometrium
The endometrium is another target of obesity. Studies of
mice with diet-induced obesity demonstrated that endo-
metrial decidualization is impaired [51]. These results were
conﬁrmed in in vitro and in vivo human studies, where a
decreased stromal decidualization was observed in women
with obesity [52]. The pathogenesis of this phenomenon
may lie on proinﬂammatory cytokines and ROS inducing
endothelial dysfunction [53] and on haptoglobulin, an
inﬂammatory marker whose endometrial levels of expres-
sion have been found to be increased in women with obesity
who had recurrent miscarriages [54]. In addition, in a recent
study, the ERK signal transduction, which belongs to
MAPK/ERK pathways, necessary for invasion of tropho-
blasts into the endometrium, was found to be down-
regulated during implantation in women with obesity [55].
All these phenomena represent possible mechanisms of
decreased implantation and high miscarriage rates in
women with obesity. It has also been suggested a condition
of reduced endometrial receptivity in obesity due to many
factors, in particular the relative hyperestrogenemia, the
reduction of glycodelin and of IGFBP1 that follow insulin
resistance and hyperinsulinemia, and the dysregulation of
leptin pathways [56–58]. Leptin, other than modulating
endometrial receptivity, exerts a regulatory role in remo-
deling the endometrial epithelium and in stimulating pro-
liferation and apoptotic cell pathways [58]. All these data
support the notion that infertility in obesity in sustained by
an unfavorable intrauterine milieu and impaired endometrial
receptivity, other than by an altered oocyte quality.
Obesity and assisted conception
Several clinical studies have focused on the impact of
female obesity on the outcome of assisted reproduction
technology (ART). Up to date, although some studies have
not reported adverse effect of obesity on ART outcomes
[59–63], most studies have linked obesity with negative
ART outcomes. In particular, obesity is associated with the
need for higher doses of gonadotropins, fewer oocytes
collected, higher number of cycles canceled for poor or high
oocytes retrieved (overstimulation), higher miscarriage rates
and reduced pregnancy and live-birth rates [64–66].
Moreover, a speciﬁc meta-analysis made by Rittenberg
et al. that included 33 studies for a total of 47,967 IVF/ICSI
cycles interestingly demonstrated that the poorer outcome
of IVF treatment was not limited to women with obesity,
but included also women with overweight [67].
The elevated doses of gonadotropins used to compensate
for the relative gonadotropin resistance induced by obesity
may be deleterious for fertility, leading to impairment of
uterine receptivity and of embryonic development and
implantation [68–70].
In summary, it is widely accepted that overweight and
obesity negatively impact the ART outcomes in women.
Accordingly, it has been observed that a reduction in body
weight is able to improve IVF treatment success in term of
number of oocytes retrieved, number of mature oocytes
developed and pregnancy rate [71, 72].
Obesity and pregnancy outcome
Maternal obesity increases the risk of complications in
pregnancy, labor, and birth for both the mother and the
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neonate. In fact, maternal obesity in associated with
increased rates of pregnancy complications, mainly in the
third trimester [73, 74], as well as increased rates of fetal
malformations [75, 76] and increased risk of intrauterine
fetal death and of death of the neonate in the ﬁrst year of life
[73, 77]. In addition, neonates of mothers with obesity have
increased rates of neonatal complications such as head
trauma, shoulder dystocia, brachial plexus lesions, fractures
of the clavicle, meconium aspiration, and respiratory dis-
tress [73, 77].
Fertility after weight loss
Many interventions have been studied to reduce the effect of
obesity on infertility, including weight loss, dietary factors,
physical activity and bariatric surgery but, to date, there are still
no precise indications on how to solve the problem in the most
effective way. Clark and colleagues [78] showed that weight
loss in obese infertile women is extremely effective for the
resumption of ovulation, improvement of spontaneous preg-
nancy rate, and reduction of miscarriage rate. The amount of
weight loss required for the resumption of fertility is however
unclear. Sim and colleagues recently demonstrated that a loss
of only 6.9% of initial body weight is sufﬁcient to enhance
pregnancy rates [79]. In women with massive obesity, bariatric
surgery has been shown to improve fertility, but to date there is
no consensus on the role of bariatric surgery in the manage-
ment of infertility-associated obesity within the medical com-
munity. Musella and coworkers described a 78.5% of
pregnancies in obese infertile women after weight loss induced
by Bioenterics Intragastric Balloon (BIB) treatment [80]. The
beneﬁcial effect of bariatric surgery on anovulatory infertility
was demostrated in a survey study of 195 anovulatory obese
women who regained ovulation in 71% of cases after surgery
[81]. However, a recently performed pilot study demonstrated
that a brief intensive weight loss intervention in subfertile
women with severe obesity resulted in improvement in ovu-
lation similarly to bariatric surgery [82]. More studies are
warranted to corroborate these interesting results.
Obesity and polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is one of the most
common causes of anovulatory infertility in women. Obe-
sity, that affects approximately half of PCOS women [83],
aggravates infertility through the negative impact on men-
ses, ovulation, as well as pregnancy and live birth rates [84,
85]. Moreover, a blunted responsiveness to pharmacologi-
cal treatments to induce ovulation, as well as higher gona-
dotropin requirements during ART stimulation with,
however, fewer oocytes recruited, have been described in
obese with respect to non-obese PCOS [86, 87]. Patho-
physiological mechanisms by which obesity negatively
impacts fertility in PCOS are complex and not completely
understood. Undoubtedly, obesity aggravates hyperan-
drogenism and insulin resistance, and is associated with
hyposomatotropinism in PCOS, particularly in abdominal
obesity [19, 88, 89]. The important impact of obesity in
aggravating infertility in PCOS is supported by the studies
that demonstrate that lifestyle interventions, including
dietary advice and standardized physical activity programs,
have a signiﬁcant positive impact on ovulation, menses
abnormalities and infertility [90, 91], and these beneﬁcial
effects have been observed even after modest weight loss of
5–10% [92–94]. Studies on the effects of bariatric surgery
in women with severe obesity and PCOS reported inter-
esting data on the beneﬁts of sustained weight loss on fer-
tility. In particular, a recent meta-analysis [95] demonstrated
that after 1 year from bariatric surgery in women with
severe obesity and PCOS, the prevalence of menstrual
irregularities decreased from 56.2 to 7.7% and the pre-
valence of infertility declined from 18.2 to 4.3%.
Conclusion
In conclusion, obesity is associated with infertility in women
through multiple and complex mechanisms that are sum-
marized in Fig. 1. Brieﬂy, obesity is associated with high
serum leptin levels due to leptin produced by the adipose
tissue. Leptin acts at the level of the ovary and of the endo-
metrium where it inhibits both human granulosa and thecal
cell steroidogenesis, which interferes with the development of
the dominant follicle and oocyte maturation, and alters
endometrial epithelium receptivity. High leptin levels may
also contribute to the development of peripheral insulin
resistance. On the other hand, the condition of selective leptin
resistance at central level that accompanies obesity reduces
stimulation of GnRH. Obesity, particularly the abdominal
phenotype, is also associated with an increase in E2, E1 and
in some androgens, such as T, DHT, androstenedione, and
dehydroepiandrosterone for an increased synthesis and sto-
rage at the level of the adipose tissue, and with a parallel
decrease in SHBG circulating levels, with a consequent
increased delivery of androgens and estrogens to target tis-
sues. The exposure of the ovary at high androgen levels
produces premature follicular atresia, thus contributing to
anovulation. On the other hand, hyperestrogenemia may have
a detrimental effect upon endometrial receptivity, thus con-
tributing to infertility. Hyperandrogenemia, hyperleptinemia,
but also high FFA and cytokines such as Interleukin-6 (IL6)
and Tumor Necrosis Factor-α (TNFα) contribute to induce a
state of insulin resistance, that interestingly affects classic
target tissues of insulin action (i.e., muscle, liver and adipose
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tissue), but not the ovaries. The ovary, under the effect of
hyperinsulinemia that compensates insulin resistance, syn-
thetizes more androgens, particularly A and T that cause
premature follicular atresia. Hyperinsulinemia and excess of
circulating FFA, in association with a dysregulation of
GHRH, SS, and ghrelin pathways contribute to determine the
low GH status that accompanies obesity and that could con-
tribute to affect ovarian and endometrial functions. Accu-
mulation of FFA within the ovary is also associated with ER
stress, mitochondrial dysfunction of the oocytes, and apop-
tosis of the cumulus–oocyte complexes, with a consequent
delayed meiotic maturation, increased aneuploidia and folli-
cular apoptosis. In addition, high FFA and cytokines and a
reduction of glycodelin and of IGFBP1 that follow insulin
resistance and hyperinsulinemia interfere with endometrial
decidualization, the necessary step for uterine receptivity.
Weight loss is able to restore fertility in most cases.
However, nowadays, there are no convincing studies to
guide the choice of the best method to be used to induce
weight loss among physical activity, diet and bariatric sur-
gery and to tailoring therapy.
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